The mechanism of action (MoA) of a clickable fatty acid
analogue
8-(2-cyclobuten-1-yl)octanoic acid (DA-CB) has been investigated for
the first time. Proteomics, metabolomics, and lipidomics were combined
with a network analysis to investigate the MoA of DA-CB against Mycobacterium smegmatis (Msm). The
metabolomics results showed that DA-CB has a general MoA related to
that of ethionamide (ETH), a mycolic acid inhibitor that targets enoyl-ACP
reductase (InhA), but DA-CB likely inhibits a step downstream from
InhA. Our combined multi-omics approach showed that DA-CB appears
to disrupt the pathway leading to the biosynthesis of mycolic acids,
an essential mycobacterial fatty acid for both Msm and Mycobacterium tuberculosis (Mtb). DA-CB decreased keto-meromycolic acid biosynthesis.
This intermediate is essential in the formation of mature mycolic
acid, which is a key component of the mycobacterial cell wall in a
process that is catalyzed by the essential polyketide synthase Pks13
and the associated ligase FadD32. The multi-omics analysis revealed
further collateral alterations in bacterial metabolism, including
the overproduction of shorter carbon chain hydroxy fatty acids and
branched chain fatty acids, alterations in pyrimidine metabolism,
and a predominate downregulation of proteins involved in fatty acid
biosynthesis. Overall, the results with DA-CB suggest the exploration
of this and related compounds as a new class of tuberculosis (TB)
therapeutics. Furthermore, the clickable nature of DA-CB may be leveraged
to trace the cellular fate of the modified fatty acid or any derived
metabolite or biosynthetic intermediate.